cc-5013
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Xinhua Hospital, Shanghai Jiao Tong University School of MedicinePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 81/ 100
Competitive context
52 Active assets in the Adult Nasal Type Extranodal NK/T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PEGASPARGASE CStone Pharmaceuticals | Phase 4 | BBB |
DEXAMETHASONE Mingzhi Zhang | Phase 4 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Centre, Singapore | Phase 4 | BBB |
Tucidinostat Ruijin Hospital | Phase 4 | BB |
ETOPOSIDE Tarapeutics Science Inc. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →